Citations

Clear

3042 citation(s) found for "Kumar, S".

Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study
Kálmán, János , Papiol, Sergi , Forstner, Andreas J. , Heilbronner, Urs , Degenhardt, Franziska , Adli, Mazda , Adorjan, Kristina , Akula, Nirmala , Alda, Martin , Anderson‐Schmidt, Heike , Andlauer, Till F. M. , Anghelescu, Ion‐George , Ardau, Raffaella , Arias, Bárbara , Arolt, Volker , Aubry, Jean‐Michel , Bartholdi, Kim, Bauer, Michael , Benabarre, Antonio , Bengesser, Susanne , Bhattacharjee, Abesh Kumar, Birner, Armin , Brichant‐Petitjean, Clara, Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Clark, Scott R. , Comes, Ashley L. , Cruceanu, Cristiana , Czerski, Piotr M. , Zompo, Maria Del , Dietrich, Detlef E. , Étain, Bruno , Ethofer, Thomas , Falkai, Peter , Fallgatter, Andreas J. , Figge, Christian, Flatau, Laura , Folkerts, Here, Frisén, Louise , Frye, Mark A. , Fullerton, Janice M. , Gade, Katrin , Gard, Sébastien, Grigoroiu‐Serbânescu, Maria , Gryaznova, Anna, Hake, Maria, Jäger, Markus , Jamain, Stéphane , Jiménez, Esther , Juckel, Georg , Kahn, Jean‐Pierre, Kassem, Layla, Kittel‐Schneider, Sarah , Kliwicki, Sebastian , Klohn‐Sagatholislam, Farah, Köller, Manfred , Konrad, Carsten , Lackner, Nina , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Leckband, Susan G. , Maj, Mario , Manchia, Mirko , Martinsson, Lina , McCarthy, Michael J. , McMahon, Francis J. , Mitjans, Marina , Mondimore, Francis M. , Nieratschker, Vanessa , Novák, Tomáš , Ösby, Urban, Potash, James B. , Reich‐Erkelenz, Daniela , Reif, Andreas , Reimer, Jens , Reininghaus, Eva Z. , Reitt, Markus , Ripke, Stephan , Schalling, Martin , Scherk, Harald, Schmauß, Max, Schubert, Klaus Oliver , Schulte, Eva C. , Schulz, Sybille, Senner, Fanny , Severino, Giovanni , Shekhtman, Tatyana , Shilling, Paul D. , Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Stegmaier, Sophia, Stierl, Sebastian, Stopková, Pavla , Thiel, Andreas , Tighe, Sarah K., Tortorella, Alfonso , Turecki, Gustavo , Vieta, Eduard , Veeh, Julia, Hagen, Martin von, Wigand, Moritz E. , Wiltfang, Jens , Zandi, Peter P. , Zimmermann, Jörg , Heilbronner, Maria , Etain, B , Vieta, E , Cichon, Sven , Alda, Martin , Ripke, Stephan , Fullerton, Janice M , Strohmaier, Jana , Aubry, Jean‐Michel , Backlund, Lena , Baune, Bernhard , Becker, Thomas M , Bellivier, Frank , Biernacka, Joanna M. , Budde, Monika , Colom, Francesc , Dannlowski, Udo , Dayer, Alexandre G. , DePaulo, J Raymond , Garnham, Julie , Goes, Fernando , Gryaznova, Anna, Hauser, Joanna , Herms, Stefan , Hoffmann, Per , Hou, Liping , Kelsoe, John R , Klöhn-Sagatholislam, Farahnaz, König, Barbara , Lang, Fabian U. , McElroy, Susan L. , Mitchell, Philip B , Monteleone, Palmiero , Nievergelt, Caroline M , Pfennig, Andrea , Reininghaus, Eva , Rouleau, Guy Armand , Rybakowski, Janusz K , Schofield, Peter R. , Spitzer, Carsten , Squassina, Alessio , Witt, Stephanie H. , Wright, A. Jordan , Nöthen, Markus M. , Rietschel, Marcella , Schulze, Thomas , Papiol, Sergi , Heilbronner, Urs , Cruceanu, Cristiana , Czerski, Piotr , Jamain, Stéphane , Grigoroiu-Serbanescu, Maria , Kalman, Janos , Schulte, Eva , Wiltfang, Jens , Andlauer, Till , Kittel-Schneider, Sarah , Lavebratt, Catharina , Leboyer, Marion , Tortorella, Alfonso , McCarthy, Michael , Novak, Tomas , Reif, Andreas , Stopkova, Pavla , Turecki, Gustavo , McMahon, Francis , Arias, Bárbara , Schubert, Klaus Oliver , Mitjans, Marina , Manchia, Mirko

Mayo Clinic

Bipolar Disorders | June 28, 2018 | Volume: 21 | Issue: 1 | Pages: 68-75

10.1111/bdi.12659 | PMID 29956436 Get It

Objectives Bipolar disorder (BD) with early disease onset is associated with an unfavorable clinical outcome and constitutes a clinically and biologically homogenous subgroup within the heterogeneous BD spectrum. Previous studies have found an accumulation of early age at onset (AAO) in BD families and have therefore hypothesized that there is a larger genetic contribution to the early‐onset cases than to late onset BD. To investigate the genetic background of this subphenotype, we evaluated whether an increased polygenic burden of BD‐ and schizophrenia (SCZ)‐associated risk variants is associated with an earlier AAO in BD patients. Methods A total of 1995 BD type 1 patients from the Consortium of Lithium Genetics (ConLiGen), PsyCourse and Bonn‐Mannheim samples were genotyped and their BD and SCZ polygenic risk scores (PRSs) were calculated using the summary statistics of the Psychiatric Genomics Consortium as a training data set. AAO was either separated into onset groups of clinical interest (childhood and adolescence [≤18 years] vs adulthood [>18 years]) or considered as a continuous measure. The associations between BD‐ and SCZ‐PRSs and AAO were evaluated with regression models. Results BD‐ and SCZ‐PRSs were not significantly associated with age at disease onset. Results remained the same when analyses were stratified by site of recruitment. Conclusions The current study is the largest conducted so far to investigate the association between the cumulative BD and SCZ polygenic risk and AAO in BD patients. The reported negative results suggest that such a polygenic influence, if there is any, is not large, and highlight the importance of conducting further, larger scale studies to obtain more information on the genetic architecture of this clinically relevant phenotype.
ARNT/HIF‐1β links high‐risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma
Liu, Yingmin , Yi-cheng, LU , Liu, Xiaobo , Liu, Xuelian , Ye, Long , Sun, Yue , Wang, Xue , Yang, Pei‐Yu , Gao, Sujun , Kumar, Shaji , Jin, Fengyan , Dai, Yun , Li, Wei , Dai, Yun , Wu, Chuan, Yang, Ting , Yang, Yanping , Li, Qingchao , Yu, Xiaoyuan

Mayo Clinic

Cancer Medicine | June 21, 2018 | Volume: 7 | Issue: 8 | Pages: 3899-3911

10.1002/cam4.1596 | PMID 29926531 Get It

Abstract1q21 gain is a common cytogenetic abnormality featuring high‐risk multiple myeloma (HRMM). However, the molecular mechanism underlying the adverse prognostic effect of 1q21 gain remains largely unclear. Here, we report that ARNT/HIF‐1β, a 1q21 gene, is highly expressed in HRMM and induced by microenvironmental hypoxia, which confers drug resistance and correlates with inferior outcome. Analysis of the gene expression profile database revealed that ARNT expression was upregulated in MM and increased with disease progression or in HRMM subtypes (particularly 1q21 gain), while correlated to shorter overall survival. In a cohort of 40 MM patients, qPCR further validated that ARNT expression was higher in MM patients than normal donors. MM cells carrying 1q21 gain or acquired drug resistance displayed a robust increase in HIF‐1β protein level. Hypoxia induced HIF‐1β expression via a NF‐κB‐dependent process. Notably, HIF‐1β overexpression impaired bortezomib sensitivity, whereas shRNA knockdown of ARNT reversed hypoxia‐mediated drug resistance. Together, these findings suggest that ARNT/HIF‐1β might represent a novel biomarker for risk stratification and prognosis of HRMM patients, as well as a potential therapeutic target for overcoming 1q21 gain‐ or microenvironment‐mediated and acquired drug resistance in MM.
Does obesity affect the outcomes in takotsubo cardiomyopathy? Analysis of the Nationwide Inpatient Sample database, 2010‐2014
Desai, Rupak , Singh, Sandeep , Baikpour, Maryam, Goyal, Hemant , Dhoble, Abhijeet , Deshmukh, Abhishek , Kumar, Gautam , Sachdeva, Rajesh , Sachdeva, Rajesh , Desai, Rupak

Mayo Clinic

Clinical Cardiology | June 19, 2018 | Volume: 41 | Issue: 8 | Pages: 1028-1034

10.1002/clc.22999 | PMID 29917260 Get It

BackgroundObesity can lead to increased oxidative stress which is one of the proposed mechanisms in the etiopathogenesis of takotsubo cardiomyopathy (TCM).HypothesisThe presence of obesity adversely impacts clinical outcomes in TCM patients.MethodsWe queried the Nationwide Inpatient Sample database (2010‐2014) to identify adult patients admitted with a principal diagnosis of TCM with and without obesity. We compared the categorical and continuous variables by Pearson χ2 and Student t test, respectively, in propensity‐score matched cohorts.ResultsThe study cohort comprised 612 obese TCM (weighted n = 3034) and 5696 nonobese TCM (weighted n = 28 186) patients. Obese TCM patients were more often younger and private‐insurance enrollees. Cardiac complications including acute myocardial infarction (9.0% vs 7.4%; P = 0.04), cardiac arrest (2.3% vs. 0.4%; P < 0.001), cardiogenic shock (4.3% vs. 3.2%; P = 0.03), congestive heart failure (5.0% vs. 3.8%; P = 0.02), respiratory failure (12.9% vs. 11.0%; P = 0.021) and use of mechanical hemodynamic support (Impella; 0.2% vs. 0.0%, P = 0.02) were significantly higher among obese TCM patients. There were no significant differences between the 2 groups in all‐cause mortality (1.0% vs. 0.8%; P = 0.35), arrhythmia (24.5% vs. 22.7%, P = 0.123), length of stay (3.7 ±3.5 vs. 3.7 ±3.6 days; P = 0.68), and total hospital charges ($40 780.16 vs. $42 575.14; P = 0.08).ConclusionsObese TCM patients were more susceptible to developing TCM‐related cardiac complications than were nonobese TCM patients, without any impact on all‐cause in‐hospital mortality, LOS, and hospital charges.
Causes and Predictors of Readmission in Patients With Atrial Fibrillation Undergoing Catheter Ablation: A National Population‐Based Cohort Study
Arora, Shilpkumar , Lahewala, Sopan , Tripathi, Byomesh , Mehta, Varshil , Kumar, Varun , Chandramohan, Divya , Lemor, Alejandro , Dave, Mihir, Patel, Nileshkumar , Patel, Nilay , Shantha, Ghanshyam Palamaner Subash , Viles-González, Juan F., Deshmukh, Abhishek

Mayo Clinic

Journal of the American Heart Association | June 15, 2018 | Volume: 7 | Issue: 12 | Pages: No page available

10.1161/jaha.118.009294 | PMID 29907655 Get It

Background Reducing readmission after catheter ablation ( CA ) in atrial fibrillation (AF) is important. Methods and Results We utilized National Readmission Data ( NRD ) 2010–2014. AF was identified by International Classification of Diseases, Ninth Edition, Clinical Modification (ICD‐9‐CM) diagnostic code 427.31 in the primary field, while first CA of AF was identified via ICD‐9 ‐procedure code 37.34. Any admission within 30 or 90 days of index admission was considered a readmission. Cox proportional hazard regression was used to adjust for confounders. The primary outcomes were 30‐ and 90‐day readmissions and the secondary outcome was AF recurrence. In total, 1 128 372 patients with AF were identified from January 1, 2010 to September 30, 2014. Of which 37 360 (3.3%) underwent CA . Patients aged ≥65 years and female sex were less likely to receive CA for AF . Overall, 10.9% and 16.5% of CA patients were readmitted within 30 and 90 days post‐CA, respectively. Most common causes of readmissions were arrhythmia ( AF , atrial flutter), heart failure, pulmonary causes (pneumonia, chronic obstructive pulmonary disease) and bleeding complications (gastrointestinal bleed, intracranial hemorrhage). Patients with diabetes mellitus, heart failure, coronary artery disease ( CAD ), chronic pulmonary and kidney disease, prior stroke/transient ischemic attack (TIA), female sex, length of stay ≥2 and disposition to the facility were prone to higher 30‐ and 90‐day readmissions post ‐CA . Predictors of increase in AF recurrence post‐ CA were female sex, diabetes mellitus, chronic pulmonary disease, and length of stay ≥2. Trends of 90‐day readmission and AF recurrence were found to improve over the study period. Conclusions We identified several demographic and clinical factors associated with the use of CA in AF , and short‐term outcomes of the same, which could potentially help in the patient selection and improve outcomes.
Faculty Opinions recommendation of Calcium and vitamin D supplementation are not associated with risk of incident ischemic cardiac events or death: findings from the UK biobank cohort.
Kumar, Rajiv

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732438428.793546867 Get It

Faculty Opinions recommendation of Cullin-3-RING ubiquitin ligase activity is required for striated muscle function in mice.
Kumar, Rajiv

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.733042884.793546868 Get It

Recurrent Acute Pancreatitis
Guda, Nalini M. , Muddana, Venkata , Lévy, Philippe, Garg, Pramod Kumar , Coté, Gregory A. , Uç, Aliye , Varadarajulu, Shyam , Vege, Santhi Swaroop , Chari, Suresh T. , Forsmark, Chris E. , Yadav, Dhiraj , Reddy, D. Nageshwar , Tenner, Scott, Johnson, Colin, Akisik, Fatih , Saluja, Ashok K. , Lerch, Markus M. , Mallery, J. Shawn, Freeman, Martin L. , Vege, Santhi S, Whitcomb, David C. , Chari, Suresh T

Mayo Clinic

Pancreas | June 12, 2018 | Volume: 47 | Issue: 6 | Pages: 653-666

10.1097/mpa.0000000000001053 | PMID 29894415 Get It

Abstract Recurrent acute pancreatitis (RAP) is a clinically significant problem globally. The etiology remains unclear in approximately 10% to 15% of patients despite a thorough workup. Data on natural history and efficacy of treatments are limited. We aimed to establish criteria for diagnosis, evaluate the causative factors, and arrive at a consensus on the appropriate workup and management of patients with RAP. The organizing committee was formed, and a set of questions was developed based on the current evidence, controversies, and topics that needed further research. After a vetting process, these topics were assigned to a group of experts from around the world with special interest in RAP. Data were presented as part of a workshop on RAP organized as a part of the annual meeting of the America Pancreatic Association. Pretest and Posttest questions were administered, and the responses were tabulated by the current Grades of Recommendation Assessment, Development and Evaluation system. The consensus guidelines were established in the format of a diagnostic algorithm. Several deficiencies were identified with respect to data on etiology, treatment efficacies, and areas that need immediate research.
Mild subclinical hypothyroidism is associated with paediatric dyslipidaemia
Dahl, Amanda , Iqbal, Anoop Mohamed, Lteif, Aida, Pittock, Siobhán T. , Tebben, Peter J. , Kumar, Seema , Dahl, Amanda R, Lteif, Aida N, Tebben, Peter

Mayo Clinic

Clinical Endocrinology | May 30, 2018 | Volume: 89 | Issue: 3 | Pages: 330-335

10.1111/cen.13752 | PMID 29846957 Get It

SummaryBackgroundThere is a lack of consensus on the cardiometabolic consequences of mild subclinical hypothyroidism (SCH) among children. The objective of the current study was to compare lipid profiles in children with mild SCH with those of euthyroid children.Study DesignRetrospective medical record review.PatientsChildren (ages 2‐18 years) who had undergone simultaneous measurement of TSH, free thyroxine (T4) and lipids. Lipids in children with mild SCH (TSH 5‐<10 mIU/L and normal free T4, n = 228) were compared with those in euthyroid children (n = 1215).ResultsTSH level was positively associated with total cholesterol and nonhigh density lipoprotein (non‐HDL) cholesterol [β 0.05(0.03‐0.08), P < .0001 and β 0.05(0.03‐0.08), P < .0001, respectively]. Total cholesterol was significantly higher in children and adolescents with mild SCH compared with euthyroid children (4.43 ± 1.14 mmol/L vs 4.2 ± 0.85 mmol/L, P = .0005). Similarly, non‐HDL cholesterol level was also higher in children with mild SCH relative to euthyroid children (3.08 ± 1.14 mmol/L vs 2.91 ± 0.8 mmol/L, P = .001). The adjusted odds ratio of having elevated total cholesterol and elevated non‐HDL cholesterol was greater in children with mild SCH compared with euthyroid children (OR 1.88, 95% CI; 1.28‐2.73; P = .001 and 1.72, 95% CI 1.2‐2.5; P = .003, respectively). The presence of thyroid autoimmunity was not associated with higher rates of dyslipidaemia.ConclusionsMild SCH in children and adolescents was associated with higher rates of elevated total cholesterol and elevated non‐HDL cholesterol. Randomized placebo controlled studies are warranted to determine if treatment of mild SCH in children leads to improvement in lipid profile.
Rethinking the prescription of biotin for dermatologic conditions
Kumar, Anagha , França, Katlein , França, Katlein , Kumar, Anagha Bangalore , Lotti, Torello

Mayo Clinic

Dermatologic Therapy | May 22, 2018 | Volume: 31 | Issue: 4 | Pages: e12618

10.1111/dth.12618 | PMID 29786929 Get It

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
Shmidt, Eugenia , Kochhar, Gursimran , Hartke, Justin, Meserve, Joseph , Chaudrey, Khadija, Koliani‐Pace, Jenna L., Hirten, Robert , Faleck, David M. , Barocas, Morris, Luo, Michelle , Lasch, Karen, Boland, Brigid S. , Singh, Siddharth , Casteele, Niels Vande , Sagi, Sashidhar, Fischer, Monika , Chang, Shannon, Bohm, Matthew , Lukin, Dana J. , Sultan, Keith , Hudesman, David , Kane, Sunanda V. , Loftus, Edward V. , Sandborn, William J. , Shen, Bo , Dulai, Parambir S. , Chang, Sam S. , Vande Casteele, N , Loftus, Edward V , Chilukuri, Prianka , Sagi, Sashidhar , Chang, Shannon, Swaminath, Arun C. , Gupta, Nitin Kumar , Siegel, Corey A , Sands, Bruce E , Colombel, Jean‐Frédéric , Chang, Shannon

Mayo Clinic

Inflammatory Bowel Diseases | May 18, 2018 | Volume: 24 | Issue: 11 | Pages: 2461-2467

10.1093/ibd/izy171 | PMID 29788240 Get It

Abstract Background We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. Methods Retrospective review (May 2014–December 2016) of a prospectively maintained inflammatory bowel disease (IBD) registry. Kaplan-Meier estimates were used to determine rates of LOR to VDZ . Independent predictors of LOR were identified using univariate and multivariable Cox proportional hazard regression. Success of recapturing response (>50% reduction in symptoms from baseline) and remission (complete resolution of symptoms) after dose intensification was quantified. Results Cumulative rates for VDZ LOR were 20% at 6 months and 35% at 12 months, with slightly lower rates in Crohn’s disease than in ulcerative colitis (6 months 15% vs 18% and 12 months 30% vs 39%, P = 0.03). On multivariable analysis, LOR to a tumor necrosis factor (TNF) antagonist before VDZ use was associated with an increased risk for LOR to VDZ [hazard ratio (HR) 1.93; 95% confidence interval (CI) 1.25–2.97] in all patients. For Crohn’s disease patients specifically, higher baseline C-reactive protein concentration was associated with increased risk for LOR to VDZ (HR 1.01 per mg/dL increase, 95% CI 1.01–1.02). Shortening of VDZ infusion interval from 8 to every 4 or 6 weeks recaptured response in 49% and remission in 18% of patients. Conclusions LOR to a TNF antagonist before VDZ use and higher baseline C-reactive protein are important predictors of VDZ LOR. Treatment response can be recaptured in almost half of these patients with VDZ infusion interval shortening.